Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Clinical Study on the Safety and Preliminary Efficacy of CC312 in the Treatment of Relapsed/Refractory Autoimmune Diseases

NCT07193810 is registered in ClinicalTrials.gov with CytoCares Inc as lead sponsor.

NCT NCT07193810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07193810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Clinical Study on the Safety and Preliminary Efficacy of CC312 in the Treatment of Relapsed/Refractory Autoimmune Diseases
Lead sponsor
CytoCares Inc
Phase
Phase 1
Overall status
Recruiting
Start date
September 23, 2025
Completion date
September 29, 2027
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

iim- idiopathic inflammatory myopathies, sle - systemic lupus erythematosus, ssc-systemic sclerosis